under protocol number 7051-ONC-101 entitled "A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer" (as it may be amended from time to time by Sponsor, the "Protocol"; the performance of the Protocol at all sites is